Targeting BTK through microRNA in chronic lymphocytic leukemia

Bruton’s tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Bottoni, Arianna, Rizzotto, Lara, Lai, Tzung-Huei, Liu, Chaomei, Smith, Lisa L., Mantel, Rose, Reiff, Sean, El-Gamal, Dalia, Larkin, Karilyn, Johnson, Amy J., Lapalombella, Rosa, Lehman, Amy, Plunkett, William, Byrd, John C., Blachly, James S., Woyach, Jennifer A., Sampath, Deepa
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5201097/
https://ncbi.nlm.nih.gov/pubmed/27756747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-07-727750
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados